ClinicalTrials.gg
RecruitingNCT06108414Updated Sep 19, 2024

Low-dose Versus Standard-dose Rivaroxaban in Elderly Patients With Atrial Fibrillation

A Phase 4 interventional study of low-dose rivaroxaban and Standard-dose rivaroxaban in Atrial Fibrillation, Anticoagulant Adverse Reaction and Stroke, sponsored by China National Center for Cardiovascular Diseases. Recruiting at 1 site in China. Open to participants aged 70 Years and older. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by China National Center for Cardiovascular Diseases · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
4,374
Allocation
Randomized
Ages
70 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 45 studies testing rivaroxaban in Atrial Fibrillation — 8 open to participants now, 9 under way, none of them phase 3. Rivaroxaban · Atrial Fibrillation.

Planned enrollment
5th of 45
4,374 · median 150
Started
2024
with 2 others
Phase 4
19 of 45
6 open now
Registered
42nd of 45
by date
Lead sponsor
1 of 45
China National Center for Cardiovascular Diseases

Among the 45 studies testing rivaroxaban in Atrial Fibrillation, this one is the 5th largest by planned enrollment, is one of 3 that started in 2024, is one of 19 in phase 4, and was the 42nd registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

8 of the 45 studies testing rivaroxaban in Atrial Fibrillation are open now, in 4 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About rivaroxaban

Rivaroxaban: first FDA approval 2011 (XARELTO), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 70 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies testing rivaroxaban in Atrial Fibrillation, or all of them as a file.
02

Study summary

To evaluate the efficacy and safety of low-dose versus standard-dose rivaroxaban anticoagulation therapy in elderly patients with atrial fibrillation.

03

Conditions studied

  • Atrial Fibrillation
  • Anticoagulant Adverse Reaction
  • Stroke
  • Major Adverse Cardiac Events
04

Who can participate

Ages eligible
70 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥70 years
  • Patients with atrial fibrillation (atrial fibrillation rhythm of at least 30 seconds duration recorded by or Holter within 1 year)
  • CHA2DS2-VASc score ≥2 in men and ≥3 in women
  • Able to cooperate in signing ICFs

Exclusion criteria

Exclusion criteria:

  • Moderate-to-severe mitral stenosis, or prior mechanical valve replacement surgery, or unresected atrial myxoma, or known left ventricular thrombus
  • Prior biological valve replacement or valve repair surgery within 6 months
  • Left ventricular assist device implantation status
  • Severe stroke event within 3 months or any stroke within 14 days Major stroke events were defined as those with a Modified Rankin Scale score of 3-5.

Score 3: moderately disabled, requiring some assistance but walking without assistance; Score 4: severe disability, unable to walk independently, unable to meet their own needs without the help of others; Score 5: severe disability, bedridden, incontinent, requiring ongoing care and attention

  • (TIA) occurred within 3 days
  • Transient atrial fibrillation due to reversible triggers (e.g., after cardiac surgery, pulmonary embolism, untreated hyperthyroidism)
  • Prior or planning to undergo atrial fibrillation catheter ablation, drug cardioversion, electroconversion, or major surgery in 3 months; Prior catheter or surgical ablation > 3 months without atrial fibrillation records
  • Prior or planning to undergo left atrial appendage occlusion
  • Active infective endocarditis
  • High or increasing risk for bleeding i. Traumatic surgery that has been completed within the last 3 months or is planned within the next 3 months ii. Previous severe intracranial, intraocular, spinal cord, retroperitoneal, or nontraumatic intra-articular hemorrhage.

iii. Gastrointestinal bleeding within the past year iv. Symptomatic or gastroscopic peptic ulcer within the last month v. Hemorrhagic constitution or coagulopathy vi. Difficult-controlled hypertension (180mm Hg systolic and/or 100 mm Hg diastolic)

  • Severe renal impairment (estimated ≤ 15 mL/min)
  • Active liver disease

Including but not limited to:

i. Persistent , AST > 2×; ii. TBil > 1.5×ULN; iii. Known active hepatitis A, B or C; iv. Cirrhosis

  • level \<100g/L or thrombocytopenia count \<100 × 10\^9/L
  • Having conditions warrant standard-dose or low-dose anticoagulation treatment (non-AF, such as VTE)
  • Having conditions warrant warfarin anticoagulation treatment
  • Daily dose of aspirin >100mg
  • Having received dual antiplatelet therapy or intravenous antiplatelet drugs within 5 days (note: P2Y12 receptor antagonist alone or ≤ 100mg aspirin alone can be enrolled)
  • Having received fibrinolysis treatment in 10 days or planning to use fibrinolytic drugs
  • Having conditions warrant the following medications: and P-gp inhibitors (itraconazole, ketoconazole, voriconazole, posaconazole, clarithromycin, erythromycin, fluconazole, ritonavir, dronedarone, etc.), selective serotonin reuptake inhibitors (SSRI)/serotonin norepinephrine reuptake inhibitors (SNRI) drugs (fluoxetine, paroxelin, etc.) CYP3A4 inducers (rifampicin, phenytoin, carbamazepine, phenobarbital, St. John's wort, etc.), long-term use of NSAIDs
  • Having allergic or adverse reactions to any (including but not limited to lactose, starch, etc.) in rivaroxaban tablets, including but not limited to hereditary lactose or galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption, etc.
  • Having diagnosed with malignant tumors within 6 months, or receiving radiotherapy/chemotherapy, with an expected lifespan of no more than 3 years
  • Antiphospholipid syndrome
  • Having been enrolled in another interventional clinical trial within the past 30 days or at the same time
  • Mental disorders, communication barriers, cognitive impairment, or other serious illnesses that may affect the participation in this study
  • Known poor adherence to study follow-up or taking study drugs
  • Other conditions deemed by the investigator to be inappropriate for enrollment
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
4,374 participants (estimated)

Study arms

  • Experimental
    Low-dose rivaroxaban

    15mg q.d. rivaroxaban for 2 years after randomization. The dose should be reduced in the following special conditions: 1. Creatinine clearance \<50 mL/min; 2. Body weight ≤60kg; 3. Age ≥80 years old. In the low-dose group, the dose was reduced from the usual 15mg q.d. to 10mg q.d. .

    Drug: low-dose rivaroxaban

  • Active comparator
    Standard-dose rivaroxaban

    20mg q.d. rivaroxaban for 2 years after randomization. The dose should be reduced in the following special conditions: 1. Creatinine clearance \<50 mL/min; 2. Body weight ≤60kg; 3. Age ≥80 years old. In the standard-dose group, the dose was reduced from the 20mg q.d. to 15mg q.d. .

    Drug: Standard-dose rivaroxaban

Interventions

  • DrugRivaroxabanStudies of RivaroxabanRivaroxaban pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Rivaroxaban 15mg q.d. (The dose should be reduced to 10mg q.d. in the following special populations: 1. Creatinine clearance \<50 mL/min; 2. Body weight ≤60kg; 3. Age ≥80 years old)

  • DrugRivaroxabanStudies of RivaroxabanRivaroxaban pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Rivaroxaban 20mg q.d. (The dose should be reduced to 15mg q.d. in the following special populations: 1. Creatinine clearance \<50 mL/min; 2. Body weight ≤60kg; 3. Age ≥80 years old)

06

What researchers measure

Primary outcomes

  1. Major adverse cardiovascular and cerebrovascular events(MACCE)

    A composite endpoint of clinical events including cardiovascular death, myocardial infarction, stroke, and systemic embolism was firstly recorded after randomization

    Time frame: Through study completion, an estimated average of 2 years

Secondary outcomes

  1. Bleeding events

    A composite endpoint of ISTH major bleeding events and clinically relevant non major bleeding events was recorded after randomization

    Time frame: Through study completion, an estimated average of 2 years

  2. Net clinical benefit

    A composite endpoint of all-cause death, myocardial infarction, stroke, transient ischemic attack, systemic embolism, ISTH major bleeding events and clinically relevant non major bleeding events after randomization

    Time frame: Through study completion, an estimated average of 2 years

  3. Components of all primary and secondary outcome measures

    All-cause death, myocardial infarction, stroke, transient ischemic attack, systemic embolism, ISTH major bleeding events and clinically relevant non major bleeding events after randomization

    Time frame: Through study completion, an estimated average of 2 years

07

Study locations

1 of 1 sites recruiting
  • National Clinical Research Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College
    Beijing, Beijing 100037, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Dec 2026, 27 months after the start.

Of 130 non-industry phase 4 interventional studies under Atrial Fibrillation, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 81. This study's planned 27 months is below that.

Counting every sponsor, half of 142 studies reached it within 48 months; a quarter within 27 and three quarters within 81.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 25, 2023
First posted
Oct 31, 2023
StartActual
Sep 1, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2027
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06108414
Responsible party
Sponsor
First posted
Oct 31, 2023
Start date
Sep 1, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Sep 19, 2024

Study contacts

Zhe Zheng, MD, PhD
Contact
zhengzhe@fuwai.com
+86 010 88396051

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rivaroxaban

Start the discussion